Literature DB >> 23898283

Acute porphyria presenting as epilepsia partialis continua.

Thi Phuoc Yen Tran1, Karine Leduc, Martin Savard, Nicolas Dupré, Donald Rivest, Dang Khoa Nguyen.   

Abstract

PURPOSE: The porphyrias are a defect in the biosynthesis of heme which can be associated with different neurological symptoms during acute attacks such as peripheral neuropathy, mental disturbance and seizures. So far, there have only been a few case reports of status epilepticus, none of which were of epilepsia partialis continua (EPC). We present here two cases of hereditary coproporphyria (HCP) manifesting EPC as part of the clinical presentation.
METHOD: The patients' medical charts, EEG and imaging studies were carefully reviewed.
RESULTS: Case 1 is a 49-year-old male who first presented a tonic-clonic seizure. Case 2 is a 30-year-old male who came to the emergency room for a convulsive status epilepticus. Both evolved to EPC over the next days. EPC persisted despite several antiepileptic drug trials. Diagnosis of HCP was confirmed by a high level of urine, fecal and serum porphyrins in both cases and by genetic testing in one. Over the last 3 years, the first patient has continued to present non-disabling EPC and has had four tonic-clonic seizures associated with alcohol consumption. The second patient died from brain edema one month and half after admission.
CONCLUSION: Acute porphyrias should be included in the differential diagnosis of new onset status epilepticus, including EPC. Their recognition is important as it modifies significantly patient management, since many anticonvulsants are porphyrogenic.

Entities:  

Keywords:  Acute porphyria; Epilepsia partialis continua; Status epilepticus

Year:  2013        PMID: 23898283      PMCID: PMC3724138          DOI: 10.1159/000353279

Source DB:  PubMed          Journal:  Case Rep Neurol        ISSN: 1662-680X


Introduction

The porphyrias, a group of disorders characterized by a variable catalytic defect of one of the seven enzymes in the biosynthesis of heme, are classified clinically as acute or non-acute porphyrias based on their clinical manifestations with or without neurovisceral attacks [1, 2, 3]. The major manifestations of acute porphyrias are neurological, including neuropathic abdominal pain, peripheral neuropathy, mental disturbance and seizures. Seizures affect 10–20% of patients with acute porphyria [1]. The most commonly reported types of seizures are complex partial seizures and tonic-clonic seizures [4, 5], even though EEG documentation of such seizures have been sparse. Status epilepticus has also been rarely reported. Here, we report two patients with hereditary coproporphyria (HCP) who presented with status epilepticus and an EEG documentation.

Case Summaries

Case 1

A 49-year-old right-handed man with a past medical history of Berger's disease presented to the emergency room on December 13, 2009, for a 1-min-long tonic-clonic seizure and increasing confusion over the past week. He was immediately started on acyclovir and phenytoin. The initial EEG, brain MRI and lumbar puncture were normal. Within 2 days, he developed continuous right hand myoclonic jerks compatible with epilepsia partialis continua (EPC). Repeat brain MRI performed 3 days after admission disclosed non-enhancing high T2 and FLAIR signal changes over the bilateral temporal lobes (fig. 1). Brain PET revealed focal hypermetabolism over the bilateral frontal and temporal lobes, predominantly over the left side. Repeat EEG revealed left frontotemporal periodic lateralized epileptiform discharges (fig. 2). A repeat lumbar puncture at day 3 was within normal limits. Bacteriological, viral serological (including herpes simplex virus PCR) workup, immunologic parameters as well as toxicology screen revealed no abnormal findings. While the confusion progressively waned, EPC persisted despite several antiepileptic drug trials (phenytoin, valproic acid, carbamazepine, clobazam, lamotrigine). A probable diagnosis of HPC was eventually made when urine coproporphyrins and fecal total porphyrins returned to twice the normal range (even when testing was made 9 days after admission while the patient was improving). These abnormal results could not be explained by other conditions which have previously been associated with secondary coproporphyrinurias such as abuse of toxic substances, liver diseases, malignancies, diverse hematological diseases, etc. [6]. Over the last 3 years, the patient has continued to present non-disabling EPC (manifesting only as very low-amplitude right hand myoclonic jerks) and has had a total of four tonic-clonic seizures in the context of alcohol consumption. He remains with mild memory problems and is currently treated with levetiracetam. On the last brain MRI (2 years after initial setting), T2 signal changes had decreased significantly (fig. 3).
Fig. 1

FLAIR sequence showing hyperintensity over both mesial temporal structures (a), with mild incomplete regression after 2 years (b).

Fig. 2

a EEG with left frontotemporal periodic lateralized epileptiform discharges. b Left frontotemporal periodic discharges evolving into rhythmic slow activity discharge most prominent over the left frontotemporal region (HFF = 35 Hz; LFF = 1 Hz).

Fig. 3

FLAIR image showing right hemispheric gyriform hyperintense signal changes.

Case 2

A 30-year-old man, known only for a generalized anxiety disorder, was brought to the emergency room on November 16, 2011, in convulsive status epilepticus preceded over the last 3 days by nausea, vomiting and headaches. Initial management included intravenous benzodiazepines and phenytoin followed by intubation and a perfusion of midazolam and propofol. The patient then evolved to EPC as he presented continuous left hand and mouth myoclonic jerks, very rarely associated with altered consciousness. EEG (fig. 4) showed diffuse slowing, sometime associated with right frontotemporal periodic lateralized epileptiform discharges. MRI disclosed right hemispheric gyriform increased signal on T2-weighted images, restricted diffusion on DWI/ADC images and mild midline shift to the left. Brain PET revealed focal hypermetabolism over the right frontal and temporal lobes, and to a lesser extent in the right occipital region. Two lumbar punctures were normal. As in the first patient, bacteriological, viral serological workup as well as immunologic parameters failed to disclose a plausible cause. His condition eventually worsened, with decreased level of consciousness leading to intubation, despite large spectrum antibiotics, acyclovir, several antiepileptic drug trials (phenobarbital, levetiracetam, lacosamide, topiramate, vigabatrin, gabapentin) and immunotherapy (intravenous immunoglobulins, plasma exchanges). Diagnosis of porphyria was made when results from urine, fecal and serum porphyrins returned elevated at 3 weeks after admission. One month and a half after admission and despite hematin therapy and withdrawal of porphyrinogenic drugs, the patient eventually died from brain edema secondary to the status epilepticus, after he had suffered a porphyric attack from an isoflurane trial. Later, genetic testing confirmed HCP with a rare homozygous missense G189S mutation in the coproporphyrinogen III oxidase gene.
Fig. 4

EEG showing diffuse slowing activity, right frontal subtle/blunted periodic lateralized epileptiform discharges and left-sided muscle artifacts due to left facial jerks.

Discussion

Porphyrias are uncommon, complex metabolic disorders caused by deficiencies in the activities of the seven out of eight enzymes of the heme biosynthetic pathway [3]. They are generally subdivided into acute and non-acute porphyrias on the basis of their major clinical manifestations [3]. The acute porphyrias are well-defined genetic disorders of heme biosynthesis characterized by acute life-threatening attacks of nonspecific neurologic symptoms. These acute porphyrias are comprised of acute intermittent porphyria (AIP), HCP, variegate porphyria (VP) and 5-aminolevulinic acid dehydratase porphyria (ADP) in which AIP is the most frequent type. The combined prevalence of the acute porphyrias is approximately 5 cases per 100,000 persons, they are more common in women than in men, and often generally develop during adult life. Acute porphyric attacks can be exacerbated by a variety of factors, including porphyrinogenic drugs, alcohol, endogenous hormones particularly progesterone, pregnancy, cigarette smoking, metabolic stress induced by infections or surgery and reduced caloric intake [1]. Misdiagnoses of porphyrias are common because the signs and symptoms of acute attacks are variable and may mimic many other diseases. They can present with acute neurovisceral attacks, which may be accompanied by skin lesions in HCP and VP. Abdominal pain [1], reported approximately in 85–95% of patients, is often accompanied by nausea, vomiting, constipation and diarrhea. Other symptoms include acute psychiatric symptoms, seizures, tachycardia and hypertension, and peripheral neuropathy. Seizures [1] occur in approximately 10–20% of patients with symptomatic porphyrias. The most common types of seizures reported in the literature consist of complex partial or tonic-clonic seizures. Status epilepticus is less common, having been reported on five instances only. A summary of these previously reported cases is presented in table 1 [6, 7, 8, 9, 10] along with our cases. All were adult patients. Status epilepticus was part of the initial presentation for all subjects with the presence of visceral symptoms in two. Pregnancy was a precipitating factor in two. The type of status varied greatly from convulsive status epilepticus to non-convulsive status epilepticus, complex partial status and EPC. EEG revealed non-specific periodic discharges or rhythmic focal activity. Non-surprisingly, confirmation of diagnosis led to modification of the treatment regimen with good outcome for all patients except one (case 2). Out of the previously five reported cases, 3 patients had AIP, 1 patient had VP and 1 had an unknown type of acute porphyria, while both of our patients had HCP.
Table 1

Summary of clinical, imaging, and encephalographic features of previously reported cases and our cases

In the literature
Our patients
Case 1Case 2Case 3Case 4Case 5Case 6Case 7
Age, years42482622224930
Genderfemalefemalefemalefemalefemalemalemale
Past medical historyepilepsy related to L F astrocytoma (resected 5 y earlier)AIP diagnosed at age 20 after refractory SE; 3 other SE subsequentlynone but family history of AIPnormal first pregnancynormal first pregnancyBerger's diseasegeneralized anxiety disorder
Exacerbating factorssurgery for presumed cholecystectomyleg deep venous thrombosisalprazolamsecond pregnancysecond pregnancyROH
Visceral symptomsabdominal discomfort, anorexia, episodic dark urinenausea, vomiting
Neurological symptomsdelirium, complex partial SErefractory complex partial SEconfusion, quadriparetic, labored respiration, convulsive SEdelirium, GTC seizure → convulsive SEpsychiatric symptoms GTC seizures → convulsive SEconfusion, one GTC seizure → EPCheadache, confusion, convulsive SE → EPC → NCSE
Seizure descriptionstaring, altered consciousness, complex motor behaviorR head deviation, R facial clonic jerks, R arm tonic-clonic activity, 20–120 s, ~15 to 20/hR facial and upper limb twitching (day 12) → convulsive SE (day 14)loss of consciousness, R leg clonic activity → R arm → GTC activity, 2–3 min → convulsive SEtonic-clonic seizure evolving into continuous right hand myoclonic jerksfour GTC seizures → NCSE with the L hand and mouth jerks, rarely associated with altered consciousness
MRI/scanunchanged postoperative encephalomalaciaCT: possible L hemisphere edemabiF ↑ diffusion coefficientbiT T2/FLAIRR hemispheric gyriform T2 changes + diffusion restriction; mild L midline shift
EEGbursts of spikes, poly-spikes, sharp waves, ±sharp/slow complexes over biFT leads L RL>R slowing; during seizures: rhythmic L FT theta activityduring seizures: rhythmic L F slow activity → both hemispheresL F PLEDssevere diffuse slowing; R FT PLEDs
Treatment before diagnosisPHT, CBZ, LZP, PentobarbitalLZP, PHT, LEVOXC, LEV, PHTayclovir, PHT, VPA, CBZ, CLB, LTGantibiotics, acyclovir, plasma exchange, IG, Pb, propofol, LEV, LCM, TPM, VGB,
Treatment after diagnosishigh carbohydrate diet, hematin, GPNhematin; GPN; OXC → LEV + Mghematin, propofol, GPNGPN, LZP, high carbohydrate intake, hematin, abortionabortionLEVhematin, (VGB, LEV, LCM) → GPN, plasma exchange, IG
Outcomeno further delirium over next 2 years; modest ↓ in seizure frequencyno further seizures over next 8 months of FUconvulsions stopped, alert, able to walk with support (day 16)no futher convulsion after abortionno further seizures as well as attack of hepatic porphyria over next 2 years of FUmild memory deficits, persisting but non-disabling R hand EPC; 1 GTC seizure and 1 cluster of 3 GTC seizures in the setting of ROH intake over last 3 yearsdeceased
Type of porphyriaAIPAIPAIPVPacute hepatic porphyriaHCPHCP
ReferenceYandel and Watter (1995) [7]Zaatreh et al. (2005) [8]Pandey et al. (2003) [9]Engelhardt et al. (2004) [10]Weinzierl et al. (2007) [11]

L = Left; R = right; F = frontal; T = temporal; PHT = phenytoin; CBZ = carbamazepine; Pb = phenobarbital; LZP = lorazepam; GPN = gabapentin; SE = status epilepticus;

NCSE = non-convulsive status epilepticus; PLEDs = periodic lateralized epileptiform discharges; GTC = generalized tonic-clonic; IG = immunoglobulin.

Current understanding of the pathogenesis of seizures suggests the hepatic production of a neurotoxic substance, presumably ALA [a γ-aminobutyric acid (GABA) analogue] and/or PBG which may interact with GABA or glutamate receptors [2]. A combination of endothelial dysfunction, hypoperfusion, and vasoconstriction in this setting of neurotoxicity can lead to a compromise of the blood-brain barrier and brain edema [11]. MRI may help detect changes occurring in the brain at the time of the acute attack though lesions are non-specific (cortically and/or subcortically, anterior or posterior, without or with mild enhancement, generally but not always reversible) [11, 12]. Seizures, when they occur, are a therapeutic challenge because most AEDs (phenobarbital, carbamazepine, clonazepam, phenytoin, primidone, ethosuximide, valproic acid, lamotrigine, felbamate, tiagabine, topiramate) may exacerbate attack of acute porphyria [13]. Drugs reported to be relatively safe include gabapentin [6, 8, 14], levetiracetam [7], and possibly oxcarbazepine [15].

Conclusion

Acute porphyrias may be a cause of new onset convulsive status epilepticus and EPC. Although rare, their recognition is important as it modifies significantly patient management and probably their outcome.
  15 in total

1.  Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria.

Authors:  M Hahn; O S Gildemeister; G L Krauss; J A Pepe; R W Lambrecht; S Donohue; H L Bonkovsky
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

2.  Gabapentin and propofol for treatment of status epilepticus in acute intermittent porphyria.

Authors:  C K Pandey; N Singh; N Bose; S Sahay
Journal:  J Postgrad Med       Date:  2003 Jul-Sep       Impact factor: 1.476

3.  A 22-year-old woman with severe headaches, vomiting, and tonic-clonic seizures.

Authors:  Mollie Dahlgren; Arezou Khosroshahi; John H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05-06       Impact factor: 4.794

4.  The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine.

Authors:  Paolo Ventura; Maria Domenica Cappellini; Emilio Rocchi
Journal:  Intern Emerg Med       Date:  2009-05-29       Impact factor: 3.397

5.  Posterior reversible encephalopathy syndrome in a patient with acute intermittent porphyria.

Authors:  Sa-Yoon Kang; Ji-Hoon Kang; Jay Chol Choi; Jung Seok Lee
Journal:  J Neurol       Date:  2009-12-11       Impact factor: 4.849

6.  Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report.

Authors:  B Gaida-Hommernick; K Rieck; U Runge
Journal:  Epilepsia       Date:  2001-06       Impact factor: 5.864

7.  An analysis of six cases of acute intermittent porphyria (AIP).

Authors:  Soumitra Ghosh; Pranit Kr Chaudhury; Hiranya K Goswami
Journal:  Indian J Psychiatry       Date:  2006-07       Impact factor: 1.759

8.  Refractory status epilepticus due to acute hepatic porphyria in a pregnant woman: induced abortion as the sole therapeutic option?

Authors:  K Engelhardt; E Trinka; G Franz; I Unterberger; M Spiegel; R Beer; B Pfausler; A Kampfl; E Schmutzhard
Journal:  Eur J Neurol       Date:  2004-10       Impact factor: 6.089

9.  Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma.

Authors:  M L Yandel; M R Watters
Journal:  Clin Neurol Neurosurg       Date:  1995-08       Impact factor: 1.876

Review 10.  The porphyrias: advances in diagnosis and treatment.

Authors:  Manisha Balwani; Robert J Desnick
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

View more
  3 in total

Review 1.  Antiseizure medications in critical care: an update.

Authors:  Baxter Allen; Paul M Vespa
Journal:  Curr Opin Crit Care       Date:  2019-04       Impact factor: 3.687

2.  Acute Intermittent Porphyria Presenting with Posterior Reversible Encephalopathy Syndrome: A Rare Cause of Abdominal Pain and Seizures.

Authors:  Daram Sarala Kumari; Murthy Nln Arumilli; L Siva Kumar Reddy; Duvvuru Nageshwar Reddy; Revanth Motor
Journal:  Indian J Crit Care Med       Date:  2020-08

Review 3.  Systematic review of clobazam use in patients with status epilepticus.

Authors:  Sherif Hanafy Mahmoud; Caleb Rans
Journal:  Epilepsia Open       Date:  2018-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.